Therapeutic drug monitoring during induction therapy with Ustekinumab in patients with Crohn's disease: the key to early identification of patients with inadequate response

被引：0
|
作者：
Minguez, A. [1 ]
Bastida, G. [1 ]
Terol, I. [1 ]
Argumanez, V. [1 ]
Iborra, M. [1 ]
Aguas, M. [1 ]
Moret, I. [2 ]
Cerrillo, E. [1 ]
Garrido, A. [1 ]
Tortosa, L. [1 ]
Nos, P. [1 ]
机构：
[1] La Fe Univ & Polytech Hosp, Dept Gastroenterol, Valencia, Spain
[2] La Fe Univ & Polytech Hosp, IIS Hosp La Fe, IBD Res Grp, Valencia, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P652
引用
收藏
页码：781 / 782
页数：2
相关论文
共 50 条
  • [31] Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply
    Kopylov, Uri
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (05) : 907 - 907
  • [32] Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients
    Doherty, Matthew K.
    Ding, Tao
    Koumpouras, Charlie
    Telesco, Shannon E.
    Monast, Calixte
    Das, Anuk
    Brodmerkel, Carrie
    Schloss, Patrick D.
    MBIO, 2018, 9 (02):
  • [33] Evaluation of bowel wall thickness by ultrasound as early diagnostic tool for therapeutic response in Crohn's disease patients treated with ustekinumab
    Hoffmann, Tatjana
    Fusco, Stefano
    Blumenstock, Gunnar
    Sadik, Saman
    Malek, Nisar P.
    Froehlich, Eckhart
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, : 1212 - 1220
  • [34] Predictive models for assessing the response to ustekinumab in Crohn's disease patients
    Hubert, A.
    Bottieau, J.
    Toubeau, J. F.
    Franchimont, D.
    Vallee, F.
    Liefferinckx, C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I385 - I386
  • [35] Reinduction with ustekinumab in Crohn's disease patients with a loss of response to treatment
    Heron, V.
    Restellini, S.
    Bessissow, T.
    Lemieux, C.
    Lakatos, P.
    Wild, G.
    Seidman, E.
    Bitton, A.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S326 - S326
  • [36] Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Gasink, Christopher
    Jacobstein, Douglas
    Szapary, Philippe
    Johanns, Jewel
    Gao, Long-Long
    Davis, Hugh M.
    Hanauer, Stephen B.
    Feagan, Brian G.
    Ghosh, Subrata
    Sandborn, William J.
    GASTROENTEROLOGY, 2018, 154 (06) : 1660 - 1671
  • [37] Predictive models for assessing the response to ustekinumab in Crohn's disease patients
    Hubert, A.
    Bottieau, J.
    Toubeau, J. F.
    Franchimont, D.
    Vallee, F.
    Liefferinckx, C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I385 - I386
  • [38] Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
    Li, K.
    Chan, D.
    Pollack, P.
    Jacobstein, D.
    Brodmerkel, C.
    Gasink, C.
    Feagan, B. G.
    Sandborn, W.
    Rutgeerts, P.
    De Hertogh, G.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S314 - S314
  • [39] Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients
    Claire, P.
    Severine, B.
    Nicolas, D.
    Maria, N.
    Pierre, D.
    Julien, B.
    Romain, G.
    Medina, B.
    Myriam, L.
    Benjamin, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S260 - S261
  • [40] TROUGH LEVELS AND ANTIBODIES TO USTEKINUMAB ARE NOT CORRELATED TO RESPONSE TO USTEKINUMAB TREATMENT IN CROHN'S DISEASE PATIENTS
    Claire, Painchart
    Brabant, Severine
    Duveau, Nicolas
    Nachury, Maria
    Desreumaux, Pierre
    Branche, Julien
    Gerard, Romain
    Boualit, Medina
    Labalette, Myriam
    Pariente, Benjamin
    GASTROENTEROLOGY, 2017, 152 (05) : S388 - S388
12345